Mebiopharm Co., Ltd
HomeSitemapNotes for UsageInquiry{
Introduction
Management Philosophy
Business Plan
Company Outline
History
Research & Development
Products
Transferrin Products
Transferrin Products
Map
@

@

November,20 2008

Phase II US clinical trial- Involving Hong Kong hospital 

Article in Newspaper "Nikkei Sangyo Shimbun"

November 11 , 2008

Exterminate incurable diseases by high-tech  

Article in Newspaper "Nikkei Sangyo Shimbun"

October,15 2008

Mebiopharm enters into Phase U study of MBP-426 in US  

Article in Newspaper "Nikkei Sangyo Shimbun"

October 02, 2008

Phase I study of anticancer DDS in US shown good result; starting Phase II targeting colon cancer

Nikkei Biotech online

April 28, 2008

A collaborative assignment with Keio University (Assistant Prof. Masakazu Ueda, Graduate School of Medicine; Prof. Haruma Kawaguchi, Science and Technology) and Tokyo Institute of Technology (Prof. Hiroshi Handa, Bioscience and Biotechnology; Prof. Masanori Abe, Physical Electronics) on diagnosis and treatment system development against breast cancer was adopted as Comprehensive Support Programs by Japan Science and Technology Agent  

October 25, 2007

Presentation on Open Label Phase 1 Study of MBP-426 at the AACR-NCI-EORTC International Conference in San Francisco  

April 25, 2007

Raised 9th round finance of Yen 357.9Million  

April 18, 2007

Presentation at American Association for Cancer Research (AACR) Annual Meeting 2007 in Los Angeles  

MBP-426   MBP-Y003
April 09, 2007

2nd tumor-targeting product is to enter clinical trial in November 

Article in Newspaper "Nikkei Sangyo Shimbun"

March 28, 2007

Raised 8th round finance of Yen 600.9Million  

February 01, 2007

Mebiopharm ventures into CMO, manufacturing liposome, GLP in summer

Nikkei Biotech online

January 24, 2007

Nanotech DDS drugs - Domestic power matching US companies with new technology  

Article in Newspaper "Nikkei Sangyo Shimbun"

Oct. 27, 2006

New method of DDS - Domestic power leading cancer treatment  

Nikkei Sangyo Shinbun

Sep. 28, 2006

Obtain exclusive sales agreement for Transferrin  

Nikkei Sangyo Shinbun

September 27, 2006

Obtain exclusive supply and sales agreement for Transferrin from Blood supply Netherlands; using anti cancer drug containing Oxaliplatin

Nikkei Biotech online

Aug. 28, 2006

Technologies Frontier - targeting to the tumor  

Nikkei Business 2006.8.28 issue

July 25, 2006

Hot technologies - Nanotechnology targeting to the tumor  

Nikkei Sangyo Shinbun

June 29, 2006

A new formulation targeting to the tumor  

Nikkei Sangyo Shinbun

May 8, 2006

Nanotechnologies formulation capsule zeros in on the cancer  

Nikkei Sangyo Shinbun

April 27, 2006

Mebiopharm joined an international Bio VB group  

Nikkei Sangyo Shinbun

April 26, 2006

Anticancer nanotechnology drug agent begins clinical trial in US  

Nikkei Sangyo Shinbun

April 25, 2006

Measure expression level of target molecules, aiming for early ratification to enter Phase I study in US

Nikkei Biotech online

March 27, 2006

Nanotechnology New Medication 

Nikkei Sangyo Shinbun

April 26, 2006

Mebiopharm enters into an exclusive license agreement with NOF Corporation regarding its tumor targeting platform technology

Nikkei Shinbun

December 13, 2005

Mebiopharm grant exclusive DDS production and sales to NOF cooperation; using anti cancer drug containing Oxaliplatin

Nikkei Biotech online

September 06, 2005

Apply for starting of clinical trial of new drug in US, using DDS anticancer drug; using anti cancer drug containing Oxaliplatin

Nikkei Biotech online

August 9, 2005

Mebiopharm produces DDS anti-tumor drug in the US and Asia 

Nikkan Kogyo Shinbun

June 27, 2005

New drug targeting affected organ - shown in the studies

Nikkei Shinbun 

June 02, 2005

Apply for initiating clinical trial in US in summer – using anti cancer drug containing Oxaliplatin

Nikkei Biotech online

March 18, 2005

Early promise for Mebiopharm's liposomal Oxaliplatin

Scrip   World pharmaceutical news in U.K.

February 22, 2005

Presentation at AACR - DDS technology for colorectal cancer

Nikkan Kogyo Shinbun

February 21, 2005

Anticancer DDS agent to begin clinical trial in US this autumn

The Chemical Daily

February 17, 2005

Presentation at AACR Pre-clinical study for Transferrin –modified PEG liposome containing Oxaliplatin

Nikkei Biotech online

February 17, 2005

Presentation at AACR Pre-clinical study for Transferrin –modified PEG liposome containing Oxaliplatin  In its effort to advance the adaptation of DDS technology to the development of anticancer company, we have prepared a presentation

Nikkan Yakugyo

February 16, 2005

Presentation at AACR gPre-Clinical Study for Transferrin-modified PEG liposome containing Oxaliplatinh@>>Click

October 18, 2004

Manufacturing industry \ competitiveness borne of knowledge

Nikkei Sangyo Shimbun
September 13, 2004 Silicon Valley branch office opened
September 2, 2004 NHK's "Ohayo Nippon" program on TV
August 18, 2004

Carry out third-party allocation

Nikkei Shinbun
August 10, 2004 Established U.S. office to develop new colon cancer drug
July 27, 2004

Attacking a cancer's source of nutrition: Applies to patent immunotherapeutic technique

Nikkei Sangyo Shimbun

July 19, 2004

Mebiopharm receives JETRO startup assistance in Silicon Valley -- first to move into the biotech industry

Nikkan Kogyo Shimbun

26 May, 2004 New cancer medicine delivered directly to diseased site
Commercially available as early as 2007 in U.S.
Nikkei Sangyo Shimbun, p. 1
20 May, 2004 Universities that create wealth: new venture from The Tokyo University
Nikkei Sangyo Shimbun
May, 2004 New cancer drug developed that delivers medicine directly to diseased site
Nikkei Net Advanced Medicine
10 March, 2004 First Alliance Promotion -- message from Akamaru Venture Participation
P March 2004 NIF Ventures Ltd.  Nif news March edition

Copyright© 2011 Mebiopharm Co., Ltd.@All Rights Reserved.